Edaravone: Clinical Trials

15 trials of Edaravone, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 completed, 1 unknown. 15 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 115Completed 14, Unknown 1

Follow Edaravone: new trials by email Literature Review of Edaravone trials Research Report on Edaravone

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects
TTYP01, Radicava, Radicava ORS - Healthy Adult Subjects
Phase 1CompletedShanghai Auzone Biological Technology Co., Ltd.292023-11-072026-04-24
Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric Tube
MT-1186 - Healthy Adult Subjects
Phase 1CompletedShionogi362021-02-262026-07-15
A Study of TTYP01 in Healthy Adult Subjects
TTYP01 single ascending doses, Placebo, TTYP01, 60 mg - Healthy Adult Subjects
Phase 1CompletedShanghai Auzone Biological Technology Co., Ltd.722020-04-242025-01-06
Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy
MT-1186 - Japanese Patients With ALS
Phase 1CompletedShionogi62020-01-242026-07-16
Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study)
MT-1186 - Healthy Adult Subjects
Phase 1CompletedShionogi162019-06-102026-07-15
Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection
Compound Edaravone Injection, Edaravone Injection, 2-Aminoethanesulfonic Acid Injection - Drug-drug Interaction
Phase 1CompletedNanjing Yoko Biomedical Co., Ltd.242019-05-102021-03-22
Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis
MT-1186 - Japanese Patients With ALS
Phase 1CompletedShionogi92019-04-172026-07-15
Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects
MT-1186, MCI-186 - Healthy Adult Subjects
Phase 1CompletedShionogi422019-03-222026-07-15
PK Study in Subjects With Severe Hepatic Impairment
MCI-186 - Severe Hepatic Impairment, Healthy
Phase 1CompletedShionogi122018-11-062026-07-15
Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)
MT-1186, Rosuvastatin, Sildenafil - Healthy Adult Subjects
Phase 1CompletedShionogi842018-10-172026-07-15
A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects
MCI-186, Placebo - Healthy Adult Subjects
Phase 1CompletedShionogi272018-09-182026-07-15
Study of Oral Edaravone in Healthy Adult Males
MT-1186, MT-1186-matching placebo - Healthy Adult Subjects
Phase 1CompletedShionogi742018-03-202026-07-16
Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment
MCI-186 - Hepatic Impairment, Healthy
Phase 1CompletedShionogi222016-11-162026-07-15
Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment
MCI-186 - Renal Impairment, Healthy
Phase 1CompletedShionogi302016-10-272026-07-15
Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke
autologous hematopoiesis stem cell transplantation, Aspirin, Warfarin - Stroke
Phase 1UnknownZhejiang Hospital402012-01-012012-01-25

Conditions studied

Renal Insufficiency (1)  ·  Stroke (1)

Sponsors

Shionogi (11)  ·  Shanghai Auzone Biological Technology Co., Ltd. (2)  ·  Nanjing Yoko Biomedical Co., Ltd. (1)  ·  Zhejiang Hospital (1)

Countries

Japan (10)  ·  China (2)  ·  Australia (1)  ·  Czechia (1)  ·  Hungary (1)  ·  Slovakia (1)  ·  United States (1)

Top investigators

Robert. Bass, MD (1)  ·  Sepehr Shakib, MD (1)  ·  Yaguo Li, master (1)  ·  Yumiao Zhou, master (1)

Results publications

PMID 36376130, PMID 32800532, PMID 33704925, PMID 37953075, PMID 32543120, PMID 32868037, PMID 33955162, PMID 36225132

NIH funding

2018 (1)